PT2030622E - Indicação da dose de progesterona no tratamento de um traumatismo crânio-encefálico - Google Patents

Indicação da dose de progesterona no tratamento de um traumatismo crânio-encefálico Download PDF

Info

Publication number
PT2030622E
PT2030622E PT08167618T PT08167618T PT2030622E PT 2030622 E PT2030622 E PT 2030622E PT 08167618 T PT08167618 T PT 08167618T PT 08167618 T PT08167618 T PT 08167618T PT 2030622 E PT2030622 E PT 2030622E
Authority
PT
Portugal
Prior art keywords
progesterone
dosage
indication
treatment
brain injury
Prior art date
Application number
PT08167618T
Other languages
English (en)
Inventor
Stuart W Hoffman
Arthur L Kellerman
Donald G Stein
David W Wright
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of PT2030622E publication Critical patent/PT2030622E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
PT08167618T 2005-03-24 2006-03-24 Indicação da dose de progesterona no tratamento de um traumatismo crânio-encefálico PT2030622E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66472805P 2005-03-24 2005-03-24
US72966305P 2005-10-24 2005-10-24

Publications (1)

Publication Number Publication Date
PT2030622E true PT2030622E (pt) 2011-06-02

Family

ID=36987966

Family Applications (2)

Application Number Title Priority Date Filing Date
PT06748657T PT1868614E (pt) 2005-03-24 2006-03-24 Regime de dosagem para o tratamento de uma lesão cerebral traumática com progesterona
PT08167618T PT2030622E (pt) 2005-03-24 2006-03-24 Indicação da dose de progesterona no tratamento de um traumatismo crânio-encefálico

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT06748657T PT1868614E (pt) 2005-03-24 2006-03-24 Regime de dosagem para o tratamento de uma lesão cerebral traumática com progesterona

Country Status (16)

Country Link
US (4) US20090221544A1 (pt)
EP (5) EP1871382B1 (pt)
JP (5) JP5394059B2 (pt)
AT (2) ATE520404T1 (pt)
AU (2) AU2006226774B2 (pt)
CA (2) CA2602950C (pt)
CY (2) CY1111478T1 (pt)
DE (1) DE602006020353D1 (pt)
DK (2) DK2030622T3 (pt)
ES (2) ES2392454T3 (pt)
HK (3) HK1112579A1 (pt)
HR (2) HRP20110198T1 (pt)
PL (2) PL2030622T3 (pt)
PT (2) PT1868614E (pt)
RS (1) RS52471B (pt)
WO (2) WO2006102644A2 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006226774B2 (en) 2005-03-24 2010-12-02 Emory University Methods for the treatment of central nervous system injury via a tapered administration of progesterone
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
EP2052724A1 (en) 2007-10-26 2009-04-29 sanofi-aventis Use of norgestimate as a selective inhibitor of TRPC3, TRPC6 and TRPC6 and TRPC7 ion channel
US9527881B2 (en) 2008-02-26 2016-12-27 Emory University Steroid analogues for neuroprotection
EP2331571B1 (en) 2008-09-18 2015-08-26 Northwestern University Nmda receptor modulators and uses thereof
US20110306579A1 (en) * 2009-01-30 2011-12-15 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
US20110262502A1 (en) * 2010-02-08 2011-10-27 Prairie Pharmaceuticals LLC Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc)
ES2773079T3 (es) 2010-02-08 2020-07-09 Shenzhen Evergreen Therapeutics Co Ltd Métodos para el uso de progestágeno como sensibilizador de glucocorticoides
US10987361B2 (en) 2010-02-08 2021-04-27 Shenzhen Evergreen Therapeutics Co., Ltd. Treating auto-immune and auto-inflammatory diseases
US10993879B2 (en) * 2010-02-08 2021-05-04 Shenzhen Evergreen Therapeutics Co., Ltd. Pulmonary delivery of progestogen
TW201138782A (en) 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen
MX357761B (es) * 2011-04-27 2018-07-23 Univ Northwestern Métodos para tratar la enfermedad de alzheimer, enfermedad de huntington, autismo u otros trastornos.
WO2013043985A1 (en) 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
SG10201606063RA (en) * 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
US20130210785A1 (en) 2012-02-15 2013-08-15 Emory University Progesterone analogs and uses related thereto
MX356427B (es) 2012-02-29 2018-05-29 Braun Melsungen Ag Emulsion que contiene hormona.
RU2498826C1 (ru) * 2012-05-14 2013-11-20 Федеральное государственное бюджетное учреждение науки Комплексный научно-исследовательский институт им. Х.И. Ибрагимова Российской академии наук Способ лечения больных с черепно-мозговой травмой
IL304912A (en) 2012-08-21 2023-10-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
EP2925327B1 (en) 2012-11-30 2024-01-10 The Regents of The University of California Allopregnanolone for treating, reducing or mitigating symptoms of post-partum depression
SI3514158T1 (sl) 2013-01-29 2023-03-31 Aptinyx Inc. Spirolaktamski modulatorji NMDA-receptorja in njihove uporabe
JP6531042B2 (ja) 2013-01-29 2019-06-12 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
EA201591404A1 (ru) 2013-01-29 2016-01-29 Аптиникс Инк. Спиролактамные модуляторы рецептора nmda и их применение
EA201591405A1 (ru) 2013-01-29 2017-05-31 Аптиникс Инк. Спиролактамные модуляторы nmda-рецептора и их применение
KR20150110787A (ko) 2013-01-29 2015-10-02 노렉스, 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
WO2015023593A1 (en) 2013-08-12 2015-02-19 Emory University Progesterone phosphate analogs and uses related thereto
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
US10231979B2 (en) * 2015-08-07 2019-03-19 Indiana University Research And Technology Corporation Modulation of inflammation using progesterone metabolites
WO2017156103A1 (en) 2016-03-08 2017-09-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
PE20190174A1 (es) 2016-05-19 2019-02-01 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
IL264496B (en) 2016-08-01 2022-09-01 Aptinyx Inc Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
WO2018026798A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same
BR112019001921A2 (pt) 2016-08-01 2019-05-14 Aptinyx Inc. moduladores do receptor nmda de espiro-lactama e seus usos
US10918637B2 (en) 2016-08-01 2021-02-16 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
CA3031537A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
AU2019215058A1 (en) 2018-01-31 2020-09-17 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3918336A1 (en) * 2019-01-31 2021-12-08 University of Geneva Prospective markers in traumatic brain injury (tbi)
JP2022523564A (ja) 2019-03-04 2022-04-25 アイオーカレンツ， インコーポレイテッド 機械学習を使用するデータ圧縮および通信
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
KR20240144112A (ko) * 2021-12-02 2024-10-02 마블바이옴 인코포레이티드 미주신경 관련 질환, 장애 및 병태를 치료하기 위한 마이크로바이옴 조성물, 성분 또는 대사산물의 방법 및 용도
WO2024059056A1 (en) * 2022-09-12 2024-03-21 Emory University Methods of managing traumatic brain injury

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5217085A (en) 1975-07-30 1977-02-08 Ono Pharmaceut Co Ltd Method of quantitative determination of free fatty acids in serum usin g fatty acid activating enzymes
US4404366A (en) * 1980-05-06 1983-09-13 Miles Laboratories, Inc. Beta-galactosyl-umbelliferone-labeled hapten conjugates
US4369250A (en) 1981-07-31 1983-01-18 Sherwood Medical Industries Inc. Fatty acid determination
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
USRE35517E (en) * 1987-08-25 1997-05-20 University Of Southern California Method, compositions, and compounds for modulating brain excitability
AU609927B2 (en) 1987-08-25 1991-05-09 Kelvin W. Gee Compositions and methods for alleviating stress, anxiety and seizure activity
US5512429A (en) 1989-09-19 1996-04-30 British Technology Group Limited Assay for enzyme activity
GB9105707D0 (en) 1991-03-18 1991-05-01 Wilton David C Assay
US5114388A (en) * 1991-07-26 1992-05-19 True Fitness Technology, Inc. Stair simulator exerciser with adjustable incline
US5212167A (en) * 1991-09-12 1993-05-18 Trustees Of Boston University Modulation of receptor-mediated ion transport
US5206415A (en) * 1991-12-20 1993-04-27 Washington University Tricyclic steroid analogs
CN1100541C (zh) * 1993-01-19 2003-02-05 恩多研究公司 脱氢表雄酮的治疗用途和传送系统
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
DE4311870C2 (de) 1993-04-10 1998-07-30 Altramed Holdings Ltd Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen
WO1995005826A1 (en) * 1993-08-20 1995-03-02 Jackson Meyer B Method for regulating neuropeptide hormone secretion
US5763431A (en) * 1993-08-20 1998-06-09 Jackson; Meyer B. Method for regulating neuropeptide hormone secretion
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
FR2727117A1 (fr) * 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
US5837544A (en) * 1995-02-02 1998-11-17 Cell Genesys, Inc. Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase
DE69634039T2 (de) * 1995-06-06 2005-12-08 Euro-Celtique S.A. Steroidderivate der Androstan- und der Pregnanreihe
HUP9700322A3 (en) * 1995-06-09 2001-03-28 Euro Celtique Sa Formulations and methods for providing prolonged local anesthesia
US5888996A (en) * 1995-07-26 1999-03-30 Trustees Of Boston University Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
CA2256365A1 (en) 1996-05-22 1997-11-27 Diversified Pharmaceuticals, Inc. Compositions, methods and devices for the transdermal delivery of drugs
US5763492A (en) * 1996-10-01 1998-06-09 Duguesne University Of The Holy Ghost Methods for effecting memory enhancement mediated by non-steroidal sulfatase inhibitors
AU739146B2 (en) 1997-05-02 2001-10-04 Wyeth Pregnan-3-ol-20-ones
US6245757B1 (en) * 1997-10-03 2001-06-12 Research Corporation Technologies, Inc. Use of progestins to treat ischemic event
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
US6268223B1 (en) 1999-08-27 2001-07-31 Viatech Imagin, Llc Assay for detecting damage to the central nervous system
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
AU2006226774B2 (en) * 2005-03-24 2010-12-02 Emory University Methods for the treatment of central nervous system injury via a tapered administration of progesterone

Also Published As

Publication number Publication date
EP1868614B1 (en) 2012-08-08
US20120289491A1 (en) 2012-11-15
CA2601715A1 (en) 2006-09-28
JP5394059B2 (ja) 2014-01-22
JP5295755B2 (ja) 2013-09-18
JP2008534512A (ja) 2008-08-28
WO2006102644A9 (en) 2006-11-23
AU2006226811A1 (en) 2006-09-28
ES2392454T3 (es) 2012-12-10
WO2006102596A3 (en) 2007-01-18
CY1111478T1 (el) 2015-08-05
WO2006102644A2 (en) 2006-09-28
JP2014055183A (ja) 2014-03-27
HK1112579A1 (en) 2008-09-12
EP2431042B1 (en) 2013-06-26
US20090325920A1 (en) 2009-12-31
CA2601715C (en) 2012-10-16
ES2428313T3 (es) 2013-11-07
PL1868614T3 (pl) 2013-01-31
PL2030622T3 (pl) 2011-07-29
AU2006226774B2 (en) 2010-12-02
JP2011225629A (ja) 2011-11-10
US20090221544A1 (en) 2009-09-03
EP1871382B1 (en) 2011-08-17
EP2030622B1 (en) 2011-02-23
HRP20110198T1 (hr) 2011-04-30
DK2030622T3 (da) 2011-05-02
ATE520404T1 (de) 2011-09-15
DK1868614T3 (da) 2012-11-12
CY1113253T1 (el) 2016-04-13
JP5496407B2 (ja) 2014-05-21
CA2602950A1 (en) 2006-09-28
RS52471B (en) 2013-02-28
AU2006226774A1 (en) 2006-09-28
AU2006226811B2 (en) 2010-11-25
EP1868614A2 (en) 2007-12-26
US20120245133A1 (en) 2012-09-27
EP2030622A1 (en) 2009-03-04
HK1112581A1 (en) 2008-09-12
ATE499104T1 (de) 2011-03-15
WO2006102596A2 (en) 2006-09-28
CA2602950C (en) 2012-10-30
EP2494976A1 (en) 2012-09-05
PT1868614E (pt) 2012-11-23
EP1871382A2 (en) 2008-01-02
EP2431042A1 (en) 2012-03-21
US8614203B2 (en) 2013-12-24
JP2013234191A (ja) 2013-11-21
HRP20120688T1 (hr) 2012-09-30
DE602006020353D1 (de) 2011-04-07
HK1128242A1 (en) 2009-10-23
JP2008534515A (ja) 2008-08-28
WO2006102644A3 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
HK1128242A1 (en) Indication of dosage of progesterone in the treatment of a traumatic brain injury
WO2008039898A3 (en) Methods for the treatment of a traumatic central nervous system injury
EP1648385A4 (en) SYSTEM AND METHOD FOR THE PHOTODYNAMIC TREATMENT OF COMBUSTIONS, WOUNDS AND RELATED SKIN DISEASES
HRP20150175T1 (en) Means and methods for the treatment of tumorous diseases
WO2012106444A3 (en) Methods, devices and systems for treating insomnia by inducing frontal cerebral hypothermia
PL1913947T3 (pl) Terapia skojarzona do leczenia raka
WO2005118601A3 (en) Sulfonylethyl phosphorodiamidates for use in the treatment of cancer
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
PL1704860T3 (pl) Pochodne benzamidyny do leczenia i zapobiegania zapaleniu śluzówki
IL163752A0 (en) Use of epothilones in the treatment of brain diseases associated with proliferative processes
WO2017011356A3 (en) Mcj inhibitors for use in treating drug-induced diseases and conditions
Axelrod et al. The combination of entospletinib and vincristine demonstrates synergistic activity in a broad panel of hematological cancer cell lines and anti-tumor efficacy in a DLBCL xenograft model
WO2011071981A3 (en) Anti-cytomegalovirus activity of artemisinin-derived dimers
MX2010003615A (es) Tratamiento de desordenes neurologicos.
MXPA05012696A (es) Formulaciones de agentes antiinflamatorios no esteroides para tratar angiogenesis ocular patologica.
WO2017197249A3 (en) METHODS OF TREATING HYPER-BILIRUBINEMIA USING STANNSOPORFIN AND PHOTOTHERAPY
Fourianalistyawati et al. The Effectiveness of Mindfulness Technique to Decrease Pain in University Students
WO2005120489A3 (en) Treatment of central nervous system disorders or injuries with d-methionine
GB202218314D0 (en) Vitamin a for use in the treatment of traumatic brain injury
Chefranova et al. Efficacy of mexidol in the combination with thrombolytic therapy in patients with ischemic stroke
GB202011154D0 (en) Use of cannabidiol in the treatment of seizures associated with encephaltis
GB202011126D0 (en) Use of cannabidiol in the treatment of sezures associated with mutifocal epilepsy
Peter Celecoxib/thalidomide/temozolomide
UA77025U (ru) Способ лечения больных с черепно-мозговой травмой
Khasanova et al. The use of tizanidine in combined treatment of arm poststroke spasticity